

CURRICULUM VITAE

Louis M. Neveux
PO Box 162
Hollis Center, Maine 04042

207-284-3215

Louis.neveux@maine.edu

EDUCATION

Undergraduate *Boston University*, double major: Mathematics and Economics, 1988
Magna cum Laude

CERTIFICATION

Maine State Provisional Teaching Certificate for Secondary Schools -
Mathematics

ACADEMIC APPOINTMENTS

2001-present Lecturer, Department of Mathematics and Statistics, *University of Southern Maine*, Portland, Maine.

2013-2016 Coordinator of Developmental Math, *University of Southern Maine*, Portland, Maine.

1989-2002 Instructor, Biddeford Adult and Community Education, Biddeford, Maine.

OTHER APPOINTMENTS

2005-2017 Senior Medical Statistician
Division of Medical Screening
Department of Pathology and Laboratory Medicine
Women and Infants Hospital, Providence, Rhode Island

1990-2005 Medical Statistician
Foundation for Blood Research, Scarborough, Maine.

PEER-REVIEWED PUBLICATIONS:

1. Haddow JE, Lambert-Messerlian GM, Eklund EE, **Neveux LM**, Palomaki GE: Peripheral deiodinase activity: A potential explanation for the association between maternal weight and gestational hyperglycemia. *Obstet Med*, 2017.
2. Lambert-Messerlian GM, Eklund EE, **Neveux LM**, Palomaki GE: Measuring maternal serum screening markers for Down's syndrome in plasma collected for cell-free DNA testing. *J Med Screen*, doi:10.1177/0969141316670193, [Epub ahead of print], Oct 2016.
3. Haddow JE, Craig WY, **Neveux LM**, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME: Free thyroxin during early pregnancy and risk for gestational diabetes. *PLoS One*, 11:e0149065, 2016. PMID: 26910563.
4. Haddow JE, **Neveux LM**, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME: An inverse relationship between weight and free thyroxine during early gestation among women treated for hypothyroidism. *Thyroid*, 25(8):949-953, 2015. PMID: 26061605.
5. Palomaki GE, Eklund EE, **Neveux LM**, Lambert Messerlian GM: Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: High detection with low rates of invasive procedures. *Prenat Diagn*, 35(8):789-796, 2015. PMID:25967109.
6. Lambert-Messerlian G, Eklund E, Chien EK, Rosene-Montella K, **Neveux LM**, Haddow HR, Palomaki GE: First or second trimester serum markers, or both, for predicting preeclampsia. *Pregnancy Hypertens*, 4:271-278, 2014.
7. Haddow JE, Craig WY, **Neveux LM**, Haddow RMH, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME: Implications of high free thyroxine (FT4) concentrations in euthyroid pregnancies: The FaSTER Trial. *J Clin Endocrinol Metab*, 99:2038-2044, 2014.
8. Craig WY, Palomaki GE, **Neveux LM**, Haddow JE: Maternal body mass index during pregnancy and offspring neurocognitive development. *Obstet Med*, 6:20-25, 2013.
9. Haddow JE, Craig WY, Palomaki GE, **Neveux LM**, Lambert-Messerlian G, Canick JA, Malone FD, D'Alton ME: Impact of adjusting for the reciprocal relationship between maternal weight and free thyroxine during early pregnancy. *Thyroid*, 23:225-230, 2013.
10. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, **Neveux LM**, Ehrich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA: DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. *Genet Med*, 14:296-305, 2012.
11. Craig WY, Allan WC, Kloza EM, Pulkkinen AJ, Waisbren S, Spratt DI, Palomaki GE, **Neveux LM**, Haddow JE: Mid-gestational maternal free thyroxine concentration and offspring neurocognitive development at age two years. *J Clin Endocrinol Metab*, 97:E22-E28, 2012.
12. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, **Neveux LM**, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA: DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. *Genet Med*, 13:913-920, 2011.
13. Haddow JE, **Neveux LM**, Palomaki GE, Lambert-Messerlian G, Canick JA, Grenache DG, Lu J: The relationship between PTH and 25-hydroxy vitamin D in pregnancy. *Clin Endocrinol (Oxf)*, 75:309-314, 2011.

14. Haddow JE, McClain MR, Palomaki GE, **Neveux LM**, Lambert-Messerlian G, Canick JA, Malone FD, Porter RF, Nyberg DA, Bernstein PS, D'Alton ME for the First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium: Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption. *Obstet Gynecol*, 117:287-292, 2011.
15. Haddow JE, Cleary-Goldman J, McClain MR, Palomaki GE, **Neveux LM**, Lambert-Messerlian G, Canick JA, Malone FD, Porter RF, Nyberg DA, Bernstein PS, D'Alton ME: Thyroperoxidase and thyroglobulin antibodies in early pregnancy and pre-term delivery. *Obstet Gynecol*, 116:58-62, 2010.
16. Palomaki GE, Melillo S, **Neveux LM**, Douglas MP, Dotson DW, Janssens ACJW, Balkite EA, Bradley LA: Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies. *Genet Med*, 12:772-784, 2010.
17. Lambert-Messerlian GM, Palomaki GE, **Neveux LM**, Chien E, Friedman A, Rosene-Montella K, Hayes M, Canick JA: Early onset of preeclampsia and second trimester serum markers. *Prenat Diag*, 29:1109-1117, 2009.
18. Palomaki GE, **Neveux LM**, Donnenfeld A, Lee J, McDowell G, Canick JA, Summers A, Lambert-Messerlian G, Kellner L, Zebelman A, Haddow JE: Quality assessment of routine nuchal translucency measurements: a North American laboratory perspective, *Genet Med*, 10:131-138, 2008.
19. Palomaki GE, **Neveux LM**, Knight GJ, Haddow JE, Lee JE: Estimating first-trimester combined screening performance for Down syndrome in dried blood spots versus fresh sera. *Genetics in Medicine*, Vol. 9, No. 7, p.458-463, 2007.
20. Palomaki GE, **Neveux LM**, Haddow JE, Wyatt P: Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy. *Prenat Diag*, 27:808-813, 2007.
21. Canick JA, Lambert-Messerlian GM, Palomaki GE, **Neveux LM**, Malone FD, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Saade GR, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME: Comparison of Serum Markers in First-Trimester Down Syndrome Screening. *Obstetrics & Gynecology*, Vol. 108, No. 5, p.1192-1199, 2006.
22. Ritchie RF, Palomaki GE, **Neveux LM**, Ledue TB, Craig WY, Marcovina S, Navolotskaia O: Reference distributions for apolipoproteins A1, B, and B/A1 ratios: a practical, simple and clinically relevant approach in a large cohort. *J Clin Lab Anal*, 20:209-217, 2006.
23. Ritchie RF, Palomaki GE, **Neveux LM**, Ledue TM, Marcovina S, Navolotskaia O: Reference distributions for apolipoproteins A1, B, and B/A1 ratios: comparison of a large cohort to the world's literatures. *J Clin Lab Anal*, 20:218-226, 2006.
24. Palomaki GE, Wright DE, Summers AM, **Neveux LM**, Meier C, O'Donnell A, Huang T, Knight GJ, Haddow JE: Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study. *Prenat Diag*, 26:730-739, 2006.
25. Knight GJ, Palomaki GE, **Neveux LM**, Smith DE, Kloza EM, Pulkkinen AJ, Williams J, Haddow JE: Integrated serum screening for Down's syndrome in primary obstetric practice. *Prenat Diag*, 25:1162-1167, 2005.
26. Palomaki GE, Knight GJ, **Neveux LM**, Pandian R, Haddow JE: Maternal serum invasive trophoblast antigen (ITA) and first-trimester Down syndrome screening. *Clin Chem*, 51:1499-1504, 2005.
27. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for alpha2-macroglobulin: A practical, simple, and clinically relevant approach in a large cohort. *J Lab Clin Anal*, 18:139-152, 2004.

28. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O: Reference distributions for alpha2-macroglobulin: A comparison of a large cohort to the world's literature. *J Lab Clin Anal*, 18:148-152, 2004.
29. Palomaki GE, **Neveux LM**, Knight GJ, Haddow, JE, Pandian R. Maternal serum invasive trophoblast antigen (ITA) as a screening marker for Down syndrome during the second trimester. *Clin Chem*, 50:1804-1808, 2004.
30. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for complement proteins C3 and C4: A practical, simple, and clinically relevant approach in a large cohort. *J Lab Clin Anal*, 18:1-8, 2004.
31. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O: Reference distributions for complement proteins C3 and C4: A comparison of a large cohort to the world's literature. *J Lab Clin Anal*, 18:9-13, 2004.
32. Palomaki GE, **Neveux LM**, Knight GJ, Haddow, JE: Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. *Prenat Diagn*, 23:243-247, 2003.
33. Farina A, LeShane ES, Lambert-Messerlian GM, Canick JA, Lee T, **Neveux LM**, Palomaki GE, Bianchi DW: Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down syndrome pregnancy. *Clin Chem*, 49: 239-242, 2003.
34. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for serum iron and transferrin saturation: A practical, simple, and clinically relevant approach in a large cohort. *J Lab Clin Anal*, 16:237-245, 2002.
35. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O: Reference distributions for serum iron and transferrin saturation: A comparison of a large cohort to the world's literature. *J Lab Clin Anal*, 16:246-252, 2002.
36. Allan WC, Timothy K, Vincent GM, Palomaki GE, **Neveux LM**, Haddow, JE: Long QT syndrome in children: the value of rate corrected QT interval in children who present with fainting. *J Med Screen*, 8:178-182, 2001.
37. Allan WC, Timothy K, Vincent GM, Palomaki GE, **Neveux LM**, Haddow, JE: Long QT syndrome in children: the value of rate corrected QT interval and DNA analysis as screening tests in the general population. *J Med Screen*, 8:173-177, 2001.
38. Palomaki GE, **Neveux LM**: Using multiples of the median to normalize serum protein measurements. *Clin Chem Lab Med*, 39:1137-1145, 2001.
39. Knight GJ, Palomaki GE, **Neveux LM**, Haddow JE, Lambert-Messerlian GM: Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down syndrome screening. *J Med Screen*, 8:2-7, 2001.
40. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for the positive acute phase proteins α 1-acid glycoprotein (orosomucoid), α 1-antitrypsin, and haptoglobin: A practical, simple, and clinically relevant approach in a large cohort. *J Lab Clin Anal*, 14:284-292, 2000.
41. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O: Reference distributions for the positive acute phase proteins, α 1-acid glycoprotein (orosomucoid), α 1-antitrypsin, and haptoglobin: A comparison of a large cohort to the world's literature. *J Lab Clin Anal*, 14:265-270, 2000.
42. Lambert-Messerlian GM, Silver HM, Petraglia F, Luisi S, Pezzani I, Maybruck WM, Hogge WA, Hanley-Yanez K, Roberts JM, **Neveux LM**, Canick JA: Second-trimester levels of maternal serum human

chorionic gonadotropin and inhibin-A as predictors of preeclampsia in the third trimester of pregnancy. *J Soc Gynecol Investig*, Vol. 7, No. 3, 2000.

43. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for the negative acute phase proteins, albumin, transferrin and transthyretin: A practical, simple and clinically relevant approach in a large cohort. *J Lab Clin Anal*, 13:273-279, 1999.
44. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O: Reference distributions for the negative acute phase proteins, albumin, transferrin, and transthyretin: A comparison of a large cohort to the world's literature. *J Lab Clin Anal*, 13:280-286, 1999.
45. Craig WY, Rawstron MV, Rundell CA, Robinson E, Poulin SE, **Neveux LM**, Nishina PM, Keilson LM: Relationship between lipoprotein and oxidation-related variables and stheroma lipid composition in subjects undergoing coronary artery bypass graft surgery. *Arterioscler Thromb Vasc Biol*, 19: 1512-1517, 1999.
46. Haddow JE, Palomaki GE, Knight, GJ, Foster DL, **Neveux LM**: Second trimester screening for Down's syndrome using maternal serum dimeric inhibin-A. *J Med Screen*, Vol. 5, p.115-119, 1998.
47. Craig WY, **Neveux LM**, Palomaki GE, Cleveland MM, Haddow JE: Lipoprotein(a) as a Risk Factor for Ischemic Heart Disease: A Meta-Analysis of Prospective Studies. *Clin Chem*, 44:2301-2306, 1998.
48. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O, Ledue TB, Craig WY: Reference distributions for immunoglobulins A, G and M: A practical, simple and clinically relevant approach in a large cohort. *J Lab Clin Anal*, 12:363-370, 1998.
49. Ritchie RF, Palomaki GE, **Neveux LM**, Navolotskaia O: Reference distributions for immunoglobulins A, G and M: A comparison of a large cohort to the world's literature. *J Lab Clin Anal*, 12:371-377, 1998.
50. Smith JD, Miyata M, Poulin SE, **Neveux LM**, Craig WY: The relationship between apoE and serum oxidation-related variables is apoE phenotype-dependent. *Int J. Clin Lab Res*, Vol. 28, No. 2, p.116-121, 1998.
51. Knight GJ, Palomaki GE, **Neveux LM**, Fodor KK, Haddow JE: hCG and the free b-subunit as screening tests for Down syndrome. *Prenat Diagn*, 18:234-245, 1998.
52. Kellner LH, Canick JA, Palomaki GE, **Neveux LM**, Saller DN, Walker RP, Osathanondh R, Bombard AT: Levels of urinary beta-core fragment, total estriol and the ratio of the two in second trimester screening for Down syndrome. *Prenat Diagn*, 17:1135-1141, 1997.
53. **Neveux LM**, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE: Refinements in managing maternal weight adjustment for interpreting prenatal screening results. *Prenat Diagn*, 16:1115-1119, 1996.
54. Palomaki GE, **Neveux LM**, Haddow JE: Can reliable Down's syndrome detection rates be determined from prenatal screening intervention trials? *J Med Screen*, 3:12-17, 1996.
55. **Neveux LM**, Palomaki GE, Knight GJ, Haddow JE: Multiple marker screening for Down syndrome in twin pregnancies. *Prenat Diagn*, 16:29-34, 1996.
56. Craig WY, Poulin SE, **Neveux LM**, Palomaki GE, Dostal-Johnson DA, Ledue TB, Ritchie RF: Anti-oxidized LDL antibodies and antiphospholipid antibodies in healthy subjects: Relationship with lipoprotein and oxidation-related analytes. *J Autoimmunity*, 8:713-726, 1995.
57. Craig WY, Poulin SE, Palomaki GE, **Neveux LM**, Ritchie RF, Ledue TB: Oxidation-related analytes and lipid and lipoprotein concentrations in healthy subjects. *Arterioscler Thromb Vasc Biol*, 15:733-739, 1995.

58. Haddow JE, Knight GJ, Palomaki GE, **Neveux LM**, Chilmonczyk BA: Replacing creatinine with specific gravity to adjust urine cotinine concentrations. *Clin Chem*, 40:562-564, 1994.
59. Ledue TB, **Neveux LM**, Palomaki GE, Ritchie RF, Craig WY: The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. *Clin Chim Acta*, 223:73-82, 1993.
60. Craig WY, Poulin SE, DiGeorge AM, Forster NR, **Neveux LM**, Ledue TB, Ritchie RF: The molecular weights of twelve apolipoprotein(a) variants determined using haptoglobin 2-2 polymer molecular weight standards. *Appl Theor Electro*, 3:241-246, 1993.
61. Chilmonczyk BA, Salmun LM, Megathlin KN, **Neveux LM**, Palomaki GE, Knight GJ, Pulkkinen AJ, Haddow JE: Association between exposure to environmental tobacco smoke and exacerbations of asthma in children. *N Engl J Med*, 328:1665-1669, 1993.
62. Craig WY, Poulin SE, Forster NR, **Neveux LM**, Wald NJ, Ledue TB: Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme-linked immunosorbent assay kits. *Clin Chem*, 38:550-553, 1992.
63. Craig WY, Forster NR, Ledue TB, Johnson AM, **Neveux LM**, Ritchie RF: An improved method for determining high molecular weights by protein immunoblotting: application to apolipoprotein(a) phenotyping. *Appl Theor Electro*, 2:135-140, 1991.

ABSTRACTS / LETTERS / POSTER SESSIONS

1. Palomaki GE, **Neveux LM**, Bahado-Singh RO: Deciding which human chorionic gonadotropin-related molecule to use in a first trimester Down syndrome screening program. ACOG 55th Annual Clinical Meeting, San Diego, CA, May 5-9, 2007, *Obstet Gynecol*, 109 (4 Suppl):93S, 2007.
2. Palomaki GE, Knight GJ, **Neveux LM**, Haddow JE., Pandian R: First-trimester Down syndrome screening (response to Hallahan). *Clin Chem*, 52:161, 2006.
3. Lambert-Messerlian GM, Palomaki GE, Knight GJ, **Neveux LM**, Canick JA, Haddow JE: Dimeric inhibin-A as a marker for Down syndrome in the first trimester. Annual meeting of the American College of Medical Genetics, Orlando, Florida, March 4-7, 2004.
4. Knight GK, Palomaki GE, **Neveux LM**, Haddow JE, Bradley LA: Maternal serum dimeric inhibin-A as a second trimester screen for Down syndrome. *Am J Hum Genet*, 63:a166, 1998.
5. Palomaki GE, **Neveux LM**, Haddow JE: Current Down syndrome risk estimates are reliable. *Am J Obstet Gynecol*, Vol. 178, No. 4, p.871-872, 1998.
6. Palomaki GE, **Neveux LM**, Knight GJ, Haddow JE: Maternal weight and first trimester Down syndrome screening. *Am J Hum Genet*, 61:a160, 1997.
7. McCue BK, **Neveux LM**, Palomaki GE, Peipert JF, Canick JA: Use of triple marker screening for multiple gestation. American College of Obstetricians and Gynecologists; 1996 District I Junior Fellow Annual Meeting.

8. Bradley LA, Haddow JE, Palomaki GE, **Neveux LM**: Assessing feasibility of population screening for hemochromatosis: A meta-analysis of published studies. 2nd Annual Meeting of The American College of Medical Genetics. 1995.
9. Palomaki GE, **Neveux LM**, Haddow JE: Are DADs (discriminant aneuploidy detection) as good as MOMs (multiples of the median)? *Am J Obstet Gynecol.* Vol. 173, No. 6, p.1895-1897, 1995.
10. Simon JM, Palomaki GE, **Neveux LM**, Donnemfeld AE: The effect of fetal sex and gestational age on the BPD/FL ratio in normal and Down syndrome pregnancies. Abstract #264, 1994 Society of Perinatal Obstetricians, Las Vegas, NV.
11. Ledue TB, **Neveux LM**, Craig WY: The relationship between lipoprotein(a) and the acute phase response. *Clin Chem* 38:1063, 1992.
12. Salmun LM, Chilmonczyk BA, Megathlin KN, **Neveux LM**, Knight GJ, Pulkkinen AJ, Haddow JE: The extent and impact of environmental tobacco smoke (ETS) exposure in children with asthma. *Journal of Allergy and Clinical Immunology*, Vol. 89, No. 1(Part 2), p.231, 1992.
13. Craig WY, Poulin SE, Forster NR, **Neveux LM**, Ledue TB, Ritchie RF: Apolipoprotein(a): Characterization of variants by molecular weight and by comparison with standards. *Arteriosclerosis and Thrombosis*, Vol. 11, No. 5, p.1483a, 1991.
14. Belisle LM, Case DC, **Neveux LM**: Quantitation of risk of malignant transformation in patients with "benign" monoclonal gammopathy. *Clinical Research* , Vol. 39, No.2, p.378a, 1991.